Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression - PubMed (original) (raw)
Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression
Lingbao Ai et al. Cancer Res. 2006.
Abstract
Cystatin M is a secreted inhibitor of lysosomal cysteine proteases. Several lines of evidence indicate that cystatin M is a tumor suppressor important in breast malignancy; however, the mechanism(s) that leads to inactivation of cystatin M during cancer progression is unknown. Inspection of the human cystatin M locus uncovered a large and dense CpG island within the 5' region of this gene (termed CST6). Analysis of cultured human breast tumor lines indicated that cystatin M expression is either undetectable or in low abundance in several lines; however, enhanced gene expression was measured in cells cultured on the DNA demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC). Increased cystatin M expression does not correlate with a cytotoxic response to 5-aza-dC; rather, various molecular approaches indicated that the CST6 gene was aberrantly methylated in these tumor lines as well as in primary breast tumors. Moreover, 60% (12 of 20) of primary tumors analyzed displayed CST6 hypermethylation, indicating that this aberrant characteristic is common in breast malignancies. Finally, preinvasive and invasive breast tumor cells were microdissected from nine archival breast cancer specimens. Of the five tumors displaying CST6 gene methylation, four tumors displayed methylation in both ductal carcinoma in situ and invasive breast carcinoma lesions and reduced expression of cystatin M in these tumors was confirmed by immunohistochemistry. In summary, this study establishes that the tumor suppressor cystatin M is a novel target for epigenetic silencing during mammary tumorigenesis and that this aberrant event can occur before development of invasive breast cancer.
Similar articles
- Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation.
Chen X, Cao X, Dong W, Xia M, Luo S, Fan Q, Xie J. Chen X, et al. Biochem Biophys Res Commun. 2010 Jan 1;391(1):1070-4. doi: 10.1016/j.bbrc.2009.12.022. Epub 2009 Dec 10. Biochem Biophys Res Commun. 2010. PMID: 20004178 - Frequent epigenetic inactivation of cystatin M in breast carcinoma.
Schagdarsurengin U, Pfeifer GP, Dammann R. Schagdarsurengin U, et al. Oncogene. 2007 May 10;26(21):3089-94. doi: 10.1038/sj.onc.1210107. Epub 2006 Nov 13. Oncogene. 2007. PMID: 17099723 - Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.
Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. Ai L, et al. Carcinogenesis. 2006 Jul;27(7):1341-8. doi: 10.1093/carcin/bgi379. Epub 2006 Feb 25. Carcinogenesis. 2006. PMID: 16501252 - DNA methylation and breast carcinogenesis.
Widschwendter M, Jones PA. Widschwendter M, et al. Oncogene. 2002 Aug 12;21(35):5462-82. doi: 10.1038/sj.onc.1205606. Oncogene. 2002. PMID: 12154408 Review. - Towards novel anti-cancer strategies based on cystatin function.
Keppler D. Keppler D. Cancer Lett. 2006 Apr 28;235(2):159-76. doi: 10.1016/j.canlet.2005.04.001. Cancer Lett. 2006. PMID: 15893421 Review.
Cited by
- Zebrafish Discoveries in Cancer Epigenetics.
Chernyavskaya Y, Kent B, Sadler KC. Chernyavskaya Y, et al. Adv Exp Med Biol. 2016;916:169-97. doi: 10.1007/978-3-319-30654-4_8. Adv Exp Med Biol. 2016. PMID: 27165354 Free PMC article. Review. - Cystatin E/M suppresses legumain activity and invasion of human melanoma.
Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R. Briggs JJ, et al. BMC Cancer. 2010 Jan 15;10:17. doi: 10.1186/1471-2407-10-17. BMC Cancer. 2010. PMID: 20074384 Free PMC article. - TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB. D'Costa ZC, et al. Oncotarget. 2014 Mar 30;5(6):1609-20. doi: 10.18632/oncotarget.1707. Oncotarget. 2014. PMID: 24742492 Free PMC article. - Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer.
Veena MS, Lee G, Keppler D, Mendonca MS, Redpath JL, Stanbridge EJ, Wilczynski SP, Srivatsan ES. Veena MS, et al. Genes Chromosomes Cancer. 2008 Sep;47(9):740-54. doi: 10.1002/gcc.20576. Genes Chromosomes Cancer. 2008. PMID: 18506750 Free PMC article. - CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X, Liang Y, Lian C, Peng F, Xiao Y, He Y, Ma C, Wang Y, Zhang P, Deng Y, Su Y, Luo C, Kong X, Yang Q, Liu T, Hu G. Li X, et al. Theranostics. 2021 Oct 11;11(20):9821-9832. doi: 10.7150/thno.62187. eCollection 2021. Theranostics. 2021. PMID: 34815788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous